Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fludroxycortide is a synthetic, moderately potent topical corticosteroid used for its anti-inflammatory, antipruritic, and vasoconstrictive properties. In the STOP trial conducted by the University Hospital Birmingham NHS Foundation Trust, it is formulated as Haelan tape—a medicated adhesive tape containing 4 micrograms of fludroxycortide per square centimeter. This specific formulation is being investigated for the treatment of hypergranulation (over-granulation) at peritoneal dialysis catheter exit sites, where it aims to reduce excessive tissue growth and inflammation. The drug functions as a glucocorticoid receptor agonist, modulating gene transcription to inhibit the release of inflammatory cytokines and stabilize lysosomal membranes. While traditionally licensed for recalcitrant dermatoses such as psoriasis and eczema, its application in hypergranulation represents a targeted use for managing wound healing complications around medical devices.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fludroxycortide.